FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378265> ?p ?o ?g. }

• W4308378265 abstract "<h3>Background</h3> Components of lipid profile seem to impact differently on phenotype and activity of immune cells in cancer.^1,2 Their prognostic role in solid cancer patients treated with immune checkpoint inhibitors (ICIs) is still matter of debate. <h3>Methods</h3> We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile [total cholesterol (TC), triglycerides (TGs), low-density lipoproteins (LDL), high-density lipoproteins (HDL)] of consecutive solid cancer patients treated with ICIs and we investigated their impact on clinical outcomes. Cut-off values showing alteration of plasma lipid profile were ≥200 mg/dl for TC, ≥170 mg/dl for TGs, ≥130 mg/dl for LDL, <40 mg/dl for HDL in males, <45 mg/dl for HDL in females. <h3>Results</h3> Among 432 patients enrolled, 67% (N=289) were men, 61% (N=266) were diagnosed with advanced non-small cell lung cancer and 86.6% (N=374) of patients were treated with ICIs as monotherapy. Patients’ circulating lipid assessments were described in tables (tables 1–3). At a median follow-up of 46 months, patients with TC≥200 mg/dl showed an improved, although not significant, progression free survival (PFS) (6.61 versus 4.67 months, p=0.4) and longer overall survival (OS) (19.4 versus 10.8 months, p=0.02) compared to those with TC<200 mg/dl. Conversely, patients with TGs≥170 mg/dl showed a shorter PFS (2.8 versus 5.07 months, p=0.006) and OS (5.92 versus 12.99 months, p<0.001) compared to those with TGs<170 mg/dl. Then, we combined TC and TGs in a LIPID-score that identified three subgroups: good risk (GR) (TC≥200 mg/dl and TGs<170 mg/dl), intermediate risk (IR) (TC<200 mg/dl and TGs<170 mg/dl or TC≥200 mg/dl and TGs≥170 mg/dl) and poor risk (PR) (TC<200 mg/dl and TGs≥170 mg/dl). The median PFS of GR, IR and PR groups was 7.76, 4.18 and 2.40 months, respectively (p<0.001). Moreover, median OS of GR, IR and PR was 20.36, 11.18 and 4.14 months, respectively (p<0.001) (figure 1). At multivariate analyses, after adjusting for baseline performance status, histology, treatment line, sex, statin use, number of metastatic sites and body mass index, the impact of LIPID score remained significant for both PFS and OS (table 4). Looking at TC components, HDL and LDL, a significant association was detected only for HDL and OS, with patients characterized by higher HDL levels showing longer OS (15.3 vs 10.1 months, p=0.02). <h3>Conclusions</h3> LIPID score seems to strongly define subgroups of patients treated with ICIs with different prognosis. Further mechanistic insights are needed to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs. <h3>References</h3> Howie D, Ten Bokum A, Necula AS, Cobbold SP, Waldmann H. The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival. <i>Front Immunol</i>. 2018;<b>8</b>:1949. Published 2018 Jan 12. doi:10.3389/fimmu.2017.01949 Bonacina F, Coe D, Wang G, et al. Myeloid apolipoprotein E controls dendritic cell antigen presentation and T cell activation. <i>Nat Commun</i>. 2018;<b>9</b>(1):3083. Published 2018 Aug 6. doi:10.1038/s41467-018-05322-1 <h3>Ethics Approval</h3> Ethical approval to conduct this study was obtained by the respective local ethical committees on human experimentation of each participating center, after previous approval by the coordinating center (’Comitato Etico Regionale delle Marche – C.E.R.M.’, Reference Number 792). All study related procedures and data collection were conducted in accordance with the Declaration of Helsinki and in accordance with Good Clinical Practice. <h3>Consent</h3> Not applicable" @default.
• W4308378265 created "2022-11-11" @default.
• W4308378265 creator A5000527699 @default.
• W4308378265 creator A5003036217 @default.
• W4308378265 creator A5009428093 @default.
• W4308378265 creator A5012176145 @default.
• W4308378265 creator A5013913173 @default.
• W4308378265 creator A5016891693 @default.
• W4308378265 creator A5016921916 @default.
• W4308378265 creator A5016931919 @default.
• W4308378265 creator A5019053015 @default.
• W4308378265 creator A5021783060 @default.
• W4308378265 creator A5030638327 @default.
• W4308378265 creator A5032833091 @default.
• W4308378265 creator A5042216932 @default.
• W4308378265 creator A5047481473 @default.
• W4308378265 creator A5049850318 @default.
• W4308378265 creator A5058293814 @default.
• W4308378265 creator A5060954139 @default.
• W4308378265 creator A5062065961 @default.
• W4308378265 creator A5062204649 @default.
• W4308378265 creator A5062803920 @default.
• W4308378265 creator A5067409424 @default.
• W4308378265 creator A5069173263 @default.
• W4308378265 creator A5074937265 @default.
• W4308378265 creator A5075790876 @default.
• W4308378265 creator A5085306324 @default.
• W4308378265 date "2022-11-01" @default.
• W4308378265 modified "2023-10-18" @default.
• W4308378265 title "91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors" @default.
• W4308378265 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0091" @default.
• W4308378265 hasPublicationYear "2022" @default.
• W4308378265 type Work @default.
• W4308378265 citedByCount "0" @default.
• W4308378265 crossrefType "proceedings-article" @default.
• W4308378265 hasAuthorship W4308378265A5000527699 @default.
• W4308378265 hasAuthorship W4308378265A5003036217 @default.
• W4308378265 hasAuthorship W4308378265A5009428093 @default.
• W4308378265 hasAuthorship W4308378265A5012176145 @default.
• W4308378265 hasAuthorship W4308378265A5013913173 @default.
• W4308378265 hasAuthorship W4308378265A5016891693 @default.
• W4308378265 hasAuthorship W4308378265A5016921916 @default.
• W4308378265 hasAuthorship W4308378265A5016931919 @default.
• W4308378265 hasAuthorship W4308378265A5019053015 @default.
• W4308378265 hasAuthorship W4308378265A5021783060 @default.
• W4308378265 hasAuthorship W4308378265A5030638327 @default.
• W4308378265 hasAuthorship W4308378265A5032833091 @default.
• W4308378265 hasAuthorship W4308378265A5042216932 @default.
• W4308378265 hasAuthorship W4308378265A5047481473 @default.
• W4308378265 hasAuthorship W4308378265A5049850318 @default.
• W4308378265 hasAuthorship W4308378265A5058293814 @default.
• W4308378265 hasAuthorship W4308378265A5060954139 @default.
• W4308378265 hasAuthorship W4308378265A5062065961 @default.
• W4308378265 hasAuthorship W4308378265A5062204649 @default.
• W4308378265 hasAuthorship W4308378265A5062803920 @default.
• W4308378265 hasAuthorship W4308378265A5067409424 @default.
• W4308378265 hasAuthorship W4308378265A5069173263 @default.
• W4308378265 hasAuthorship W4308378265A5074937265 @default.
• W4308378265 hasAuthorship W4308378265A5075790876 @default.
• W4308378265 hasAuthorship W4308378265A5085306324 @default.
• W4308378265 hasBestOaLocation W43083782651 @default.
• W4308378265 hasConcept C121608353 @default.
• W4308378265 hasConcept C126322002 @default.
• W4308378265 hasConcept C143998085 @default.
• W4308378265 hasConcept C203014093 @default.
• W4308378265 hasConcept C2776256026 @default.
• W4308378265 hasConcept C2778163477 @default.
• W4308378265 hasConcept C2778270857 @default.
• W4308378265 hasConcept C71924100 @default.
• W4308378265 hasConcept C8891405 @default.
• W4308378265 hasConcept C90924648 @default.
• W4308378265 hasConceptScore W4308378265C121608353 @default.
• W4308378265 hasConceptScore W4308378265C126322002 @default.
• W4308378265 hasConceptScore W4308378265C143998085 @default.
• W4308378265 hasConceptScore W4308378265C203014093 @default.
• W4308378265 hasConceptScore W4308378265C2776256026 @default.
• W4308378265 hasConceptScore W4308378265C2778163477 @default.
• W4308378265 hasConceptScore W4308378265C2778270857 @default.
• W4308378265 hasConceptScore W4308378265C71924100 @default.
• W4308378265 hasConceptScore W4308378265C8891405 @default.
• W4308378265 hasConceptScore W4308378265C90924648 @default.
• W4308378265 hasLocation W43083782651 @default.
• W4308378265 hasOpenAccess W4308378265 @default.
• W4308378265 hasPrimaryLocation W43083782651 @default.
• W4308378265 hasRelatedWork W1967103478 @default.
• W4308378265 hasRelatedWork W2032912323 @default.
• W4308378265 hasRelatedWork W2148097028 @default.
• W4308378265 hasRelatedWork W2365632055 @default.
• W4308378265 hasRelatedWork W2372561159 @default.
• W4308378265 hasRelatedWork W2375344515 @default.
• W4308378265 hasRelatedWork W2380382254 @default.
• W4308378265 hasRelatedWork W2386605009 @default.
• W4308378265 hasRelatedWork W2390152934 @default.
• W4308378265 hasRelatedWork W2412727163 @default.
• W4308378265 isParatext "false" @default.
• W4308378265 isRetracted "false" @default.
• W4308378265 workType "article" @default.